Drug Trials Snapshots: ELREXFIO

Why It Matters

ELREXFIO adds a novel, T‑cell‑engaging option for heavily pretreated myeloma patients, potentially extending survival while confirmatory studies are underway.

Key Takeaways

• ELREXFIO achieved 57.7% ORR in heavily pretreated multiple myeloma.
• Responses were durable: 90% lasted ≥6 months, 80% ≥9 months.
• Safety profile includes CRS (58%) and infections; grade 3‑4 events in ~70%.
• Efficacy consistent across sex, race, and age subgroups.
• Accelerated FDA approval enables early access pending confirmatory trials.

Pulse Analysis

Multiple myeloma remains a therapeutic challenge, with most patients eventually relapsing after proteasome inhibitors, immunomodulatory drugs, and anti‑CD38 antibodies. ELREXFIO, a bispecific antibody that redirects T cells to BCMA‑expressing myeloma cells, enters a crowded BCMA space that includes CAR‑T products and antibody‑drug conjugates. Its subcutaneous administration and step‑up dosing aim to simplify delivery compared with infusion‑based regimens, positioning it as a potentially more accessible option for community oncology practices.

The pivotal NCT04649359 trial enrolled 187 patients across ten countries, focusing on 97 individuals who had exhausted at least four prior lines. An objective response rate of 57.7%—with a quarter achieving complete remission—matched or exceeded early data from competing BCMA agents, while durability metrics (90% of responders lasting six months, 80% nine months) suggest meaningful disease control. Importantly, efficacy held steady across sex, race, and age cohorts, indicating broad applicability despite the trial’s limited sample size for minority groups.

Safety considerations temper enthusiasm; cytokine release syndrome occurred in more than half of patients, and serious infections were common, necessitating enrollment in a REMS program. Nevertheless, the manageable grade 3‑4 toxicity profile and the convenience of weekly, later bi‑weekly subcutaneous dosing could drive rapid adoption, especially as insurers evaluate cost‑effectiveness against existing therapies. For Pfizer, ELREXFIO diversifies its oncology portfolio and may generate a new revenue stream while the company awaits confirmatory trial outcomes that could convert accelerated approval into full licensure.